340b drug pricing program.
Issues related to pharmacy benefit manager reform.
Health care workforce.
Health care supply chain.
Health care drug shortages.
Pandemic All-Hazard Preparedness Act Reauthorization.
The Stop Drug Shortages Act (No Bill Number) discussion draft.
H.R. 3008 - The Drug Shortage Prevention Act.
H.R. 3810 - The Drug Origin Transparency Act.
PL 118-42/H.R. 4366 - Consolidated Appropriations Act of 2024.
PL 118-47/H.R. 2882 - Consolidated Appropriations Act of 2024.
Duration: February 1, 2015
to
present
General Issues: Health Issues , Medicare/Medicaid , Pharmacy
Spending: about $2,060,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS), White House Office, Office of the Vice President of the United States
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Dean Rosen Health Policy Director, Senate Majority Leader Frist;
Staff Dir, Sen Subcmte on Public Health; Majority Health
Policy Counsel, House Cmte on Ways & Means, Subcmte on
Health; Health Policy Coordinator & Counsel; Sen Cmte on
Labor & Human Resources; Counsel & Prof Staff, Cmte on
Labor & Human Resources, Subcmte on Disability Policy;
Case Worker, Rep. R. Boschwitz
Lauren Aronson Dir., Office of Legis., CMS; Professional Staff Member, Cmte on Ways & Means; Policy Dir., White House; Policy Dir., HHS Office of Health Reform (detailed to the White House); Policy Advisor, (Rep. R. Emanuel); Health LA, (Rep. C. McCarthy)
Alyene Mlinar Pol Adv (Maj Leader Scalise); Pol Adv (Min Whip Scalise); Pol Adv (House Oversight/Govt Reform Comm); Prof Staff Member (Ways and Means Subcom on Health/Brady), Pol Adv (Sen Rep Policy Comm/Barrasso); Leg Asst (Senator Ben Sasse)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Mehlman Consulting, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on April 19.
Original Filing: 301566265.xml
Lobbying Issues
340b drug pricing program.
Issues related to pharmacy benefit manager reform.
Health care workforce.
Health care supply chain.
Health care drug shortages.
Pandemic All-Hazard Preparedness Act Reauthorization.
The Stop Drug Shortages Act (No Bill Number) discussion draft.
H.R. 3008 - The Drug Shortage Prevention Act.
H.R. 3810 - The Drug Origin Transparency Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
PL 118-42/H.R. 4366 - Consolidated Appropriations Act of 2024.
PL 118-47/H.R. 2882 - Consolidated Appropriations Act of 2024.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, Mehlman Consulting, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on Jan. 19.
Original Filing: 301532122.xml
Lobbying Issues
340b drug pricing program.
Issues related to pharmacy benefit manager reform.
Health care workforce.
Health care supply chain.
Health care drug shortages.
Pandemic All-Hazard Preparedness Act Reauthorization.
The Stop Drug Shortages Act (No Bill Number) discussion draft.
H.R. 3008 - The Drug Shortage Prevention Act.
H.R. 3810 - The Drug Origin Transparency Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, Mehlman Consulting, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301512150.xml
Lobbying Issues
340b drug pricing program.
Issues related to pharmacy benefit manager reform.
Health care workforce.
Health care supply chain.
Health care drug shortages.
Pandemic All-Hazard Preparedness Act Reauthorization.
The Stop Drug Shortages Act (No Bill Number) discussion draft.
H.R. 3008 - The Drug Shortage Prevention Act.
H.R. 3810 - The Drug Origin Transparency Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, Mehlman Consulting, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on July 20, 2023.
Original Filing: 301487043.xml
Lobbying Issues
340b drug pricing program.
Issues related to pharmacy benefit manager reform.
Health care workforce.
Health care supply chain.
Health care drug shortages.
Pandemic All-Hazard Preparedness Act Reauthorization.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Mehlman Consulting, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on April 20, 2023.
Original Filing: 301462094.xml
Lobbying Issues
340b drug pricing program.
Issues related to pharmacy benefit manager reform.
Health care workforce.
Health care supply chain.
Health care drug shortages.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Mehlman Consulting, Inc. (f/k/a Mehlman Castagnetti Rosen & Thomas, Inc.) lobbied for Vizient, Inc. , earning $60,000. The report was filed on Jan. 20, 2023.
Original Filing: 301438087.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
S. 773 - 340B Drug Pricing Program.
COVID-19 supply chain and pharmaceutical, PPE, and other health care supply chain issues.
S. 3799 - PREVENT Pandemics Act.
Environmental issues related to Health Care Providers and Health Care Services.
H.R. 2617 - Consolidated Appropriations Act, 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
H.R. 2617 - Consolidated Appropriations Act, 2023.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on Oct. 20, 2022.
Original Filing: 301417066.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
S. 773 - 340B Drug Pricing Program.
COVID-19 supply chain and pharmaceutical, PPE, and other health care supply chain issues.
S. 3799 - PREVENT Pandemics Act.
Environmental issues related to Health Care Providers and Health Care Services.
Inflation Reduction Act (H.R. 5376) Public Law No. 117-169.
H.R. 6833 - Continuing Resolution.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Inflation Reduction Act (H.R. 5376) Public Law No. 117-169.
H.R. 6833 - Continuing Resolution.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on July 20, 2022.
Original Filing: 301391542.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
S. 773 - 340B Drug Pricing Program.
COVID-19 supply chain and pharmaceutical, PPE, and other health care supply chain issues.
S. 3799 - PREVENT Pandemics Act.
Environmental issues related to Health Care Providers and Health Care Services.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on April 20, 2022.
Original Filing: 301365030.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
S. 773 - 340B Drug Pricing Program.
COVID-19 supply chain and pharmaceutical, PPE, and other health care supply chain issues.
S. 3799 - PREVENT Pandemics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301332356.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
S. 773 - 340B Drug Pricing Program.
COVID-19 supply chain and pharmaceutical, PPE, and other health care supply chain issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Unapproved Drug Initiative.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
3rd Quarter, 2021
In Q3, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301189.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
COVID-19 supply chain and pharmaceutical, PPE, and other health care supply chain issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Unapproved Drug Initiative.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
2nd Quarter, 2021
In Q2, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301288288.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
COVID-19 supply chain and pharmaceutical, PPE, and other health care supply chain issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Unapproved Drug Initiative.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
1st Quarter, 2021
In Q1, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301265031.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
COVID supply chain issues.
H.R. 1319 - American Rescue Plan Act of 2021; P.L. 117-2.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
H.R. 1319 - American Rescue Plan Act of 2021; P.L. 117-2.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Unapproved Drug Initiative.
Agencies Lobbied
Health & Human Services - Dept of (HHS)
4th Quarter, 2020
In Q4, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on Jan. 19, 2021.
Original Filing: 301236166.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
S. 1895, No Surprises Act.
S.2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127
CARES Act Implementation and H.R. 266, Paycheck Protection Program and Health Care Enhancement Act and
COVID supply chain issues
H.R. 133, Consolidated Appropriations Act, 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
S. 178, HEALS Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on Oct. 19, 2020.
Original Filing: 301216001.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
S. 1895, No Surprises Act.
S.2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136
H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123 H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127
CARES Act Implementation and H.R. 266, Paycheck Protection Program and Health Care Enhancement Act and
H.R. 6800, HEROES Acts
S. 178, HEALS Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
S. 178, HEALS Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2020
In Q2, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301196830.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
S. 1895, No Surprises Act.
S.2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136
H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123 H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127
CARES Act Implementation and H.R. 266, Paycheck Protection Program and Health Care Enhancement Act and
H.R. 6800, HEROES Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
1st Quarter, 2020
In Q1, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301173745.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
S. 1895, No Surprises Act.
S.2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
H.R. 6074, the Coronavirus Preparedness and Response Supplemental Appropriations Act - Public Law No: 116-123
H.R. 6201, the Families First Coronavirus Response Act - Public Law No: 116-127
H.R. 748, the Coronavirus Aid, Relief, and Economic Security (CARES) Act - Public Law No: 116-136
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on Jan. 21, 2020.
Original Filing: 301125843.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
S. 1895, No Surprises Act.
S.2543 - Prescription Drug Pricing Reduction Act of 2019
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301077424.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
S. 1895, No Surprises Act.
H.R.3 - Lower Drug Costs Now Act of 2019.
S.2543 - Prescription Drug Pricing Reduction Act of 2019
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on July 18, 2019.
Original Filing: 301049156.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program. S. 1895, No Surprises Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $60,000. The report was filed on April 19, 2019.
Original Filing: 301030773.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues; drug shortage issues.
340B Drug Pricing Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Healthcare transparency, costs and access to affordable medication and other healthcare items and services.
Agencies Lobbied
U.S. Senate
4th Quarter, 2018
In Q4, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. , earning $50,000. The report was filed on Jan. 17, 2019.
Original Filing: 301006278.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues.
340B Drug Discount Program issues.
Drug shortage issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug pricing; Part B CAP program.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on Oct. 18, 2018.
Original Filing: 300988875.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues.
340B Drug Discount Program issues.
Drug shortage issues.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug pricing; Part B CAP program.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300976529.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues.
340B Drug Discount Program issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300950726.xml
Lobbying Issues
Healthcare coverage; prescription drug costs; group purchasing issues.
340B Drug Discount Program issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on Jan. 19, 2018.
Original Filing: 300930741.xml
Lobbying Issues
Graham-Cassidy Amendment; Bi-partisan Healthcare Stabilization Act of 2017 (Alexander-Murray).
Healthcare coverage; prescription drug costs; group purchasing issues.
340B Drug Discount Program issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on Oct. 19, 2017.
Original Filing: 300908883.xml
Lobbying Issues
H.R. 1628 - American Health Care Act of 2017 and Senate Amendment - Better Care Reconciliation Act.
Graham-Cassidy Amendment.
Healthcare coverage; prescription drug costs; group purchasing issues.
340B Drug Discount Program issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on July 17, 2017.
Original Filing: 300886033.xml
Lobbying Issues
H.R. 1628 - American Health Care Act of 2017 and Senate Amendment - Better Care Reconciliation Act.
Healthcare coverage; prescription drug costs; group purchasing issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on April 13, 2017.
Original Filing: 300865077.xml
Lobbying Issues
H.R. 1628 - American Health Care Act of 2017.
Healthcare coverage; prescription drug costs; group purchasing issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on Jan. 19, 2017.
Original Filing: 300851434.xml
Lobbying Issues
Group purchasing organization issues.
S. 2615, Increasing Competition in Pharmaceuticals Act.
Prescription drug and inpatient drug costs.
H.R. 6, 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Group purchasing organization issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834777.xml
Lobbying Issues
Group purchasing organization issues.
S. 2615, Increasing Competition in Pharmaceuticals Act.
Prescription drug and inpatient drug costs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Group purchasing organization issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $60,000. The report was filed on July 20, 2016.
Original Filing: 300817993.xml
Lobbying Issues
Group purchasing organization issues.
S. 2615, Increasing Competition in Pharmaceuticals Act.
Prescription drug and inpatient drug costs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Group purchasing organization issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on April 13, 2016.
Original Filing: 300790751.xml
Lobbying Issues
Group purchasing organization issues.
S. 2615, Increasing Competition in Pharmaceuticals Act.
Prescription drug and inpatient drug costs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Group purchasing organization issues.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for Vizient, Inc. (formerly VHA-UHC Alliance NewCo, Inc.) , earning $50,000. The report was filed on Jan. 14, 2016.
Original Filing: 300771608.xml
Lobbying Issues
Group purchasing organization issues.
H.R. 6, the 21st Century Cures Act.
Prescription drug and inpatient drug costs.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Group purchasing organization issues.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Mehlman Castagnetti Rosen & Thomas, Inc. lobbied for VHA-UHC Alliance NewCo, Inc. , earning $50,000. The report was filed on Oct. 15, 2015.
Original Filing: 300753894.xml
Lobbying Issues
Group purchasing organization issues.
H.R. 6, the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Group purchasing organization issues.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, MEHLMAN CASTAGNETTI ROSEN BINGEL & THOMAS, INC. lobbied for VHA-UHC Alliance NewCo, Inc. (formerly filed as Novation) , earning $50,000. The report was filed on July 20, 2015.
Original Filing: 300741393.xml
Lobbying Issues
Group purchasing organization issues.
H.R. 6, the 21st Century Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Group purchasing organization issues.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, MEHLMAN CASTAGNETTI ROSEN BINGEL & THOMAS, INC. lobbied for NOVATION , earning $40,000. The report was filed on April 17, 2015.
Original Filing: 300718218.xml
Lobbying Issues
Group purchasing organization issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...